The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.
Notice of Funding Opportunities
| Title | Announcement Number | Activity Code | Clinical Trials Status Sort ascending | Expiration Date | Program Official |
|---|---|---|---|---|---|
| Understanding Chronic Conditions Understudied Among Women | RFA-OD-23-013 (R21 Clinical Trial Optional) | R21 | Clinical Trial Optional | 06/21/2024 | Goli Samimi, Ph.D., M.P.H. |
| Understanding Chronic Conditions Understudied Among Women | RFA-OD-23-014 (R01 Clinical Trial Optional) | R01 | Clinical Trial Optional | 06/21/2024 | Goli Samimi, Ph.D., M.P.H. |
| Biology of Bladder Cancer | PAR-22-219 (R21 Clinical Trial Optional) | R21 | Clinical Trial Optional | 09/08/2025 | |
| HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices | RFA-NS-23-028 (RM1 Clinical Trial Optional) | RM1 | Clinical Trial Optional | 06/10/2025 | Rachel Altshuler, Ph.D. |
| HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices | RFA-NS-23-003 (RM1 Clinical Trial Optional) | RM1 | Clinical Trial Optional | 06/10/2025 | |
| Basic Research in Cancer Health Disparities | PAR-21-323 (R21 Clinical Trial Not Allowed) | R21 | Clinical Trial Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Basic Research in Cancer Health Disparities | PAR-21-324 (R03 Clinical Trial Not Allowed) | R03 | Clinical Trial Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Basic Research in Cancer Health Disparities | PAR-21-322 (R01 Clinical Trial Not Allowed) | R01 | Clinical Trial Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics | PAR-23-280 (R21 Clinical Trial Not Allowed) | R21 | Clinical Trial Not Allowed | 01/08/2027 | Edward Sauter, M.D., Ph.D. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer | PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) | UH2, UH3 | Clinical Trial Not Allowed | 10/15/2026 | Sudhir Srivastava, Ph.D., M.P.H. |